Reimbursement Review Reports

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Generic Name Therapeutic Area Sort descending Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Celsentri Maraviroc HIV infection Do not list Complete
N/A panitumumab Left-sided metastatic colorectal cancer (mCRC) Active
BuTrans Buprenorphine transdermal patch Pain, persistent (moderate intensity) Cancelled
Velsipity etrasimod Ulcerative colitis Active
Brukinsa zanubrutinib Waldenström’s macroglobulinemia Reimburse with clinical criteria and/or conditions Complete
Alunbrig Brigatinib (ALK)-positive locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) Reimburse with clinical criteria and/or conditions Complete
Kisqali Ribociclib with Fulvestrant +Fulvestrant for HR+, HER2- advanced or metastatic breast cancer Reimburse with clinical criteria and/or conditions Complete
Ultomiris ravulizumab AChR antibody-positive generalized Myasthenia Gravis Do not reimburse Complete
Winlevi clascoterone Acne vulgaris Withdrawn
Cablivi caplacizumab Acquired thrombotic thrombocytopenic purpura (aTTP) Do not reimburse Complete